You searched for: composite clinical outcomes (Engelska - Maltesiska)

composite clinical outcomes
riżultati kliniċi komposti

clinical outcomes - gout flares requiring treatment
eżiti kliniċi - irkadar tal-gotta li jeħtieġ kura

these cases have been associated with poor clinical outcomes.
dawn il-każijiet ġew assoċjati ma’ riżultati kliniċi ħżiena.

clinical outcomes: proportion of patients requiring treatment for a gout flare
riżultati kliniċi: proporzjon ta’ pazjenti li kellhom bżonn kura għall-irkadar tal-gotta

long-term clinical outcomes in treatment-naïve gd1 patients – study 304
riżultati kliniċi fit-tul f’pazjenti b’gd1 li qatt ma rċevew kura qabel – studju 304

the longer-term effects of antibody development on clinical outcomes have not been established.
l-effetti fuq perjodu ta' żmien itwal ta' żvilupp tal-antikorpi fuq riżultati kliniċi għadhom ma ġewx stabbiliti.

secondary efficacy outcomes included the composite clinical outcome of recurrent vte and all-cause mortality.
ir-riżultati tal-effikaċja sekondarja kienu jinkludu r-riżultat kliniku tal-kompost ta’ vte rikorrenti u mortalità mill-kawżi kollha.

clinical outcomes were compared with those in an external control group derived from a retrospective review of medical records.
ir-riżultati kliniċi kienu mqabbla ma’ grupp ta’ kontroll minn barra li nkiseb minn reviżjoni retrospettiva tad-dokumenti mediċi.

the influence of cyp2c19 genotype on clinical outcomes in patients treated with clopidogrel has not been evaluated in prospective, randomised, controlled trials.
l-influwenza tal-ġenotip cyp2c19 fuq l-effetti kliniċi f’pazjenti kkurati bi clopidogrel ma ġietx evalwata f’provi prospettivi, randomised u kkontrollati.

the majority of paediatric patients treated for gist lacked data confirming c-kit or pdgfr mutations which may have led to mixed clinical outcomes.
il-biċċa l-kbira tal-pazjenti pedjatriċi kkurati għal gist ma kellhomx dejta li tikkonferma c-kit jew mutazzjonijiet pdgfr li setgħu wasslu għal riżultati kliniċi mħawdin.

1the correlation between macrolide mics and clinical outcome is weak for h. influenzae.
1 għal h.influenzae, l-konnessjoni bejn l-mic’s tal-makrolidi u r-riżultat kliniku hija dgħajfa.

however, there is no indication of a relevant impact on the clinical outcome.
madankollu, m’hemm l-ebda indikazzjoni ta’ impatt rilevanti fuq il-riżultat kliniku.

the purpose of the study was to evaluate the durability of sustained virologic response (svr) and assess the impact of continued viral negativity on clinical outcomes.
l- għan ta ’ l- istudju kienu li jiġi evalwat kemm idum ir - rispons viroloġiku sostnut (svr) u jiġi stmat l- impatt ta ’ negattività virali kontinwa fuq ir- riżultati kliniċi.

the clinical relevance of relating in vitro measures to drug potency and clinical outcome has not been established.
ir-rilevanza klinika li tagħmel konnessjoni bejn il-miżuri in vitro u l-potenza tal-mediċina u r-riżultat kliniku ma kinetx stabbilita.

the relation of multiple sclerosis disease activity as measured by mri and clinical outcome is currently not fully understood.
għadha mhiex mifhuma sew ir-relazzjoni ta’ l-attività tal- marda ta’ l-isklerożi multipla kif imkejla bl-mri, ma’ kif tidħer klinikament.

coronary patency and limited clinical outcome data showed that ami patients have been successfully treated later than 6 hours after symptom onset.
il-ftuħ koronarju u l-informazzjoni limitata dwar ir-riżultat kliniku wera li l-pazjenti ami kienu kkurati b’suċċess iktar minn 6 sigħat wara l-bidu tas-sintomi.

5 the clinical outcome of therapy can be determined after regeneration of the treated skin, approximately 12 weeks after the end of treatment.
l- eżitu kliniku tat- terapija jista 'jiġi stabbilit wara r- riġenerazzjoni tal- ġilda trattata, madwar 12- il ġimgħa wara t- tmiem tat- trattament.

clinical outcomes of pain and weight-bearing were comparable to the autograft (81% success in the osigraft group, 77% success in the autograft group).
ir-riżultati kliniċi ta’ l-uġigħ u jekk dak li jkun jiflaħx il-piż kienu komparabbli ma’ l-awtotrapjant (suċċess ta’ 81% fil-grupp osigraft, suċċess ta’ 77% fil-grupp awtotrapjant).

the clinical outcome of therapy can be determined after regeneration of the treated skin, approximately 4-8 weeks after the end of treatment.
l- eżitu kliniku tat- terapija jista 'jiġi stabbilit wara r- riġenerazzjoni tal- ġilda trattata, madwar 4- 8 ġimgħat wara t- tmiem tat- trattament.

a correlation between total medicinal product exposure divided by mic (auc/mic) and clinical outcome was observed.
kienet osservata korrelazzjoni bejn l-esponiment totali għall-prodott mediċinali diviż bil-mic (auc/mic) u r-riżultat kliniku.